Prognostic and predictive value of baseline PSMA-PETtotal tumour volume and SUVmean in metastatic castrationresistant prostate cancer in ENZA-p (ANZUP1901): a substudyfrom a multicentre, open-label, randomised, phase 2 trial

2025年9月9日